Clinical trial
Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate Hypertension
NCT00376636 · Speedel Pharma Ltd., Industry · Completed
Key facts
| NCT number | NCT00376636 |
|---|---|
| Title | Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate Hypertension |
| Official title | A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Parallel-Design, Four-Week Study to Investigate the Safety and Efficacy of the Oral Renin Inhibitor SPP635 Once Daily in Patients With Mild to Moderate Hypertension |
| Lead sponsor | Speedel Pharma Ltd., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | SPP635 (drug) |
| Enrollment | 35 |
| Start date | Oct 1, 2006 |
| Completion | May 1, 2007 |
| First posted | Sep 15, 2006 |
| Last update posted | Oct 30, 2007 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: